Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Chen, Jieer Ying et al.|Journal of Clinical Oncology|2021Cited by 417
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.Feng Bi, Feng Chen, Shukui Qin et al.|Journal of Clinical Oncology|2020Cited by 39
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.Zhenggang Ren, Stephen L. Chan, Yabing Guo et al.|Journal of Clinical Oncology|2023Cited by 25